Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 13;13(7):e0200341.
doi: 10.1371/journal.pone.0200341. eCollection 2018.

Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion

Jeong Uk Lim  1 , Chang Dong Yeo  1 , Hye Seon Kang  1 , Chan Kwon Park  1 , Ju Sang Kim  1 , Jin Woo Kim  1 , Seung Joon Kim  1 , Sang Haak Lee  1
Affiliations

Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion

Jeong Uk Lim et al. PLoS One. .

Abstract

Introduction: A combination of platelet and lymphocyte to monocyte ratio (LMR) (abbreviated as COP-LMR) has been recently evaluated as systemic inflammatory marker for prognostication in lung cancer. While previous study on COP-LMR has evaluated its prognostic value in NSCLC patients who underwent curative resections, the combination of these two markers has not been evaluated in advanced NSCLC yet.

Objectives: In this study, we evaluated the prognostic value of COP-LMR in stage IV NSCLC with malignant pleural effusion under active anticancer treatment.

Methods: Between January 2012 and July 2016, 217 patients with stage IV NSCLC and MPE undergoing active anticancer treatment were selected for evaluation. If patients had both low LMR (< 2.47) and increased platelet (> 30.0 ×10(4) mm-3), they were assigned to COP-LMR group 2. Patients with one parameter were assigned to COP-LMR group 1. If none, patients were assigned to COP-LMR group 0.

Results: Median overall survival (OS) (P < 0.001), progression free survival (PFS) (P < 0.001) and histological feature (P = 0.003) showed significant differences among COP-LMR groups. For COP-LMR groups 0, 1 and 2, median survival times were 35.9, 14.7 and 7.4 months, respectively, while median progression free times were 19.2, 13.3 and 7.4 months, respectively. Older age, male, low albumin, high CRP and high COP-LMR (0 vs 1, P = 0.021, hazard ratio (HR): 1.822, 95% confidence interval (CI): 1.096-3.027 and 0 vs 2, P = 0.003, HR: 2.464, 95% CI: 1.373-4.421) were independent predictive factors for shorter OS. Age, sex, histology, albumin, or CRP had no significant influence on PFS. High COP-LMR was the significant factor in predicting shorter PFS (0 vs 1, P = 0.116 and 0 vs 2, P = 0.007, HR: 1.902, 95% CI: 1.194-3.028).

Conclusions: A combination of pretreatment LMR and platelet levels can be used to predict short survival in stage IV NSCLC patients who underwent active anticancer treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Overall survival of the stage IV NSCLC patients.
(A): OS between high and low LMR patients; (B): OS between high and low platelet groups; (C): Overall survival of the stage IV NSCLC patients between the different COP LMR groups. OS showed significant difference between COP LMR groups 0 vs. 1 (P < 0.001) and 1 vs. 2 (P = 0.023). COP LMR: combination of platelet and lymphocyte to monocyte ratio; NSCLC: non-small cell lung cancer; OS: overall survival.
Fig 2
Fig 2. Progression free survival of the stage IV NSCLC patients.
PFS between the different COP LMR groups (P<0.001). COP-LMR: combination of platelet and lymphocyte to monocyte ratio; PFS: progression free survival.
Fig 3
Fig 3. Overall survival and progression free survival of the stage IV NSCLC patients without positive driver mutations between the different COP LMR groups.
A: OS showed significant difference (P = 0.001) between COP-LMR groups 1 and 2. OS showed no significant difference between COP-LMR groups 0 and 1 (P = 0.071); B: PFS showed decreasing tendency as the COP-LMR score is higher, however with no statistical significance (P = 0.056). COP LMR: combination of platelet and lymphocyte to monocyte ratio; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression free survival.
See this image and copyright information in PMC

References

    1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44. 10.1016/j.ccm.2011.09.001 ; PubMed Central PMCID: PMCPMC3864624. - DOI - PMC - PubMed
    1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. 10.1056/NEJMra0802714 . - DOI - PMC - PubMed
    1. Moro-Sibilot D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, Aerts J, Villatoro R, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 2015;88(2):215–22. 10.1016/j.lungcan.2015.02.011 . - DOI - PubMed
    1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. 10.1038/nature07205 . - DOI - PubMed
    1. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024–36. . - PubMed

MeSH terms